---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000026"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:07:16.761758+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated

## Summary
- Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).
- Operating loss of $(3.2)M; adjusted operating earnings (non-GAAP) of $22.3M.
- Full-year 2024 guidance reaffirmed: total revenue $580M-$620M, adjusted op. earnings $80M-$110M.
- FDA issued Complete Response Letter for SPN-830 (apomorphine infusion) in Parkinson's; resubmission after May 2024 FDA meeting.
- SPN-820 Phase IIb >50% enrolled; topline data H1 2025. SPN-817 interim data call May 23; SPN-443 Phase I planned.

## SEC filing metadata
- accession: 0001356576-24-000026
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/0001356576-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/supn-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000026
- JSON: https://secwatch.observer/filing/0001356576-24-000026.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000026.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. updated its the first quarter of 2024 guidance (reaffirmed).
  - Period: the first quarter of 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 8, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release regarding its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/0001356576-24-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.